Caricamento...
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration resistant prostate cancer
After initial response to androgen receptor targeting drugs abiraterone or enzalutamide, most patients develop progressive disease and therefore, castration resistant prostate cancer (CRPC) remains a terminal disease. Multiple mechanisms underlying acquired resistance have been postulated. Intratumo...
Salvato in:
| Pubblicato in: | Expert Rev Anticancer Ther |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4221359/ https://ncbi.nlm.nih.gov/pubmed/24927631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737140.2014.928594 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|